



PATENT
Customer No. 22,852
Attorney Docket No. 08702.0100-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#12

In re Application of:)
)
WOLFMAN et al.) Group Art Unit: 1645
)
Application No.: 10/071,499) Examiner: Unassigned
)
Filed: February 8, 2002)
)
For: MODIFIED AND STABILIZED GDF)
PROPEPTIDES AND USES)
THEREOF)

RECEIVED

MAR 14 2003

TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP
1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 13, 2003

By: Leslie A. McDonell

Leslie A. McDonell
Reg. No. 34,872

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

MAR 13 2003

INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

RECEIVED

Atty. Docket No. 08702.0100-00000	Appln. No. 10/071,499
Applicant WOLFMAN et al.	MAR 14 2003
Filing Date February 8, 2002	Group: 1645

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,639,638	06/17/97	Wozney et al.			
	5,700,911	12/23/97	Wozney et al.			
	5,914,234	06/22/99	Lee et al.			
	6,004,937	12/21/99	Wood et al.			
	6,096,506	08/01/00	Lee et al.			
	6,340,668 B1	01/22/02	Celeste et al.			
	6,437,111 B1	08/20/02	Wozney et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
WO 99/24058	05/20/99	PCT	A61K	38/18	
WO 99/45949	09/16/99	PCT	A61K	38/17	
WO 00/11163	03/02/00	PCT	C12N	15/12	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

International Search Report, mailed February 4, 2003, based on PCT/US02/30452
International Search Report, mailed February 25, 2003, based on PCT/US02/03467
McPherron et al. "Double Muscling in Cattle Due to Mutations in the Myostatin Gene" <i>PNAS</i> , 94:12457-12461 (November 1997)
Thies et al. "GDF-8 Propeptide Binds to GDF-8 and Antagonizes Biological Activity by Inhibiting GDF-8 Receptor Binding" <i>Growth Factors</i> , 18:251-259 (2000)

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449

Patent and Trademark Office - U.S. Department of Commerce